Other languages ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Real-time Estimate Cboe BZX Other stock markets 12:57:07 30/04/2024 am IST			5-day change	1st Jan Change
8.72 ^USD	+18.64%		+77.73%	+74.90%

05:06pm	Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	MT
12:52pm	Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	04:22pm
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	25/04
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	23/04
IN DIRETTA DAI MERCATI: Netweek, Ence Energia, Enel, OVS, Sogefi, Telecom Italia, ASML, Novartis, Airbus, Apple, Nvidia, Boeing...	23/04
C'est parti pour les publications de résultats à la chaîne	23/04
En Direct des Marchés : Renault, SAP, Sanofi, TotalEnergies, Novartis, Legrand, Tapestry, OVH...	23/04
EN DIRECTO DESDE LOS MERCADOS: Enagas, Ence Energia, Acerinox, Naturgy, Endesa, Telefónica, Novartis, Apple, Nvidia, Boeing...	23/04
Bolsa de Madrid: Publicación consecutiva de resultados	23/04
US FDA approves ImmunityBio's bladder cancer therapy	23/04
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	23/04
U.S. FDA approves ImmunityBio's bladder cancer therapy	23/04
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
ImmunityBio Announces Data from A Phase 1 Pilot Study	05/03
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	21/02
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	21/02
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	05/02
US Equity Markets Close Lower Tuesday Ahead of Fed Meeting Minutes	03/01
Sector Update: Health Care Stocks Gain Late Afternoon	03/01
Sector Update: Health Care Stocks Rise Tuesday Afternoon	03/01
ImmunityBio Secures $320 Million Investment From Oberland Capital	02/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Other languages

Filters